Anbio Biotechnology vs Nuwellis
Anbio Biotechnology and Nuwellis are similar in size: $8.6m and $8.3m of revenue in their latest fiscal years. Anbio Biotechnology grew faster (5.6% against -5.4%). Anbio Biotechnology kept more of each dollar of sales as profit: a net margin of 74.1% against -211.9%. Anbio Biotechnology carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Anbio BiotechnologyNNNN, 2025 | NuwellisNUWE, 2025 |
|---|---|---|
| Revenue | $8.6m | $8.3m |
| Revenue growth | 5.6% | -5.4% |
| Net income | $6.4m | −$17.5m |
| Operating margin | 66.7% | -134.3% |
| Net margin | 74.1% | -211.9% |
| Return on equity | 27.0% | — |
| Free cash flow | — | −$10.9m |
| Cash | $7.8m | $1.1m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 24 |
| Market value | $158m | $3.2m |
| Price vs our value range | — | — |
| Moat score | — | 33 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |